JAK-STAT signaling in cancer: From cytokines to non-coding genome.
JAK-STAT signaling in cancer: From cytokines to non-coding genome.
复制标题
癌症中的JAK-STAT信号传导：从细胞因子到非编码基因组。
DOI：
10.1016/j.cyto.2016.06.017
复制
发表时间：
2016-11
期刊：
影响因子：
3.8
通讯作者：
Kenner L
中科院分区：
文献类型：
--
作者：
Pencik J;Pham HT;Schmoellerl J;Javaheri T;Schlederer M;Culig Z;Merkel O;Moriggl R;Grebien F;Kenner L
在过去的几十年中，Janus激酶（JAK）和信号转导和转录激活因子（STAT）信号转导的研究已经发现了高度保守的程序连接细胞因子信号转导的基本细胞机制，如增殖，入侵，生存，炎症和免疫的调节。JAK/STAT途径的抑制剂用于治疗自身免疫性疾病，例如类风湿性关节炎或牛皮癣。JAK/STAT信号传导异常已被鉴定为有助于癌症进展和转移发展。靶向JAK/STAT通路是目前前列腺癌、造血系统恶性肿瘤和肉瘤最有希望的治疗策略之一。值得注意的是，新发现的JAK/STAT信号调节因子，非编码RNA转录物及其作为重要靶点和潜在临床生物标志物的作用在本文中得到了强调。除了JAK/STAT信号通路在传统细胞因子信号传导中的既定作用之外，非编码RNA还增加了另一层隐藏的调节和功能。了解癌症中非编码RNA与JAK/STAT信号传导的串扰至关重要，不仅在预后方面，而且在治疗背景下，可能会导致更好的患者分层。
In the past decades, studies of the Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) signaling have uncovered highly conserved programs linking cytokine signaling to the regulation of essential cellular mechanisms such as proliferation, invasion, survival, inflammation and immunity. Inhibitors of the JAK/STAT pathway are used for treatment of autoimmune diseases, such as rheumatoid arthritis or psoriasis. Aberrant JAK/STAT signaling has been identified to contribute to cancer progression and metastatic development. Targeting of JAK/STAT pathway is currently one of the most promising therapeutic strategies in prostate cancer (PCa), hematopoietic malignancies and sarcomas. Notably, newly identified regulators of JAK/STAT signaling, the non-coding RNAs transcripts and their role as important targets and potential clinical biomarkers are highlighted in this review. In addition to the established role of the JAK/STAT signaling pathway in traditional cytokine signaling the non-coding RNAs add yet another layer of hidden regulation and function. Understanding the crosstalk of non-coding RNA with JAK/STAT signaling in cancer is of critical importance and may result in better patient stratification not only in terms of prognosis but also in the context of therapy.
登录
查看更多内容
影响因子：
56.9
作者：
Carninci, P;Kasukawa, T;Hayashizaki, Y
通讯作者：
Hayashizaki, Y
影响因子：
82.9
作者：
Chen, CD;Welsbie, DS;Sawyers, CL
通讯作者：
Sawyers, CL
影响因子：
7.3
作者：
Chen Z;Carracedo A;Lin HK;Koutcher JA;Behrendt N;Egia A;Alimonti A;Carver BS;Gerald W;Teruya-Feldstein J;Loda M;Pandolfi PP
通讯作者：
Pandolfi PP
宇宙（癌症中的体细胞突变目录）数据库和网站。
影响因子：
8.8
作者：
Bamford, S;Dawson, E;Forbes, S;Clements, J;Pettett, R;Dogan, A;Flanagan, A;Teague, J;Futreal, PA;Stratton, MR;Wooster, R
通讯作者：
Wooster, R
影响因子：
3.7
作者：
Collins AS;McCoy CE;Lloyd AT;O'Farrelly C;Stevenson NJ
通讯作者：
Stevenson NJ